Masimo (NASDAQ:MASI) Releases Q3 2024 Earnings Guidance

Masimo (NASDAQ:MASI) issued an update on its third quarter 2024 earnings guidance on Wednesday morning. The company provided EPS guidance of 0.810-0.860 for the period, compared to the consensus EPS estimate of 0.830. The company issued revenue guidance of $495.0 million-$515.0 million, compared to the consensus revenue estimate of $502.2 million. Masimo also updated its Q3 guidance to $0.81-0.86 EPS.

Masimo Trading Up 6.0 %

Masimo stock opened at $133.77 on Thursday. The company has a debt-to-equity ratio of 0.55, a current ratio of 2.09 and a quick ratio of 1.15. The firm’s 50 day moving average price is $116.15 and its 200-day moving average price is $124.92. Masimo has a 1 year low of $75.22 and a 1 year high of $153.93. The stock has a market cap of $7.11 billion, a P/E ratio of 91.00 and a beta of 0.98.

Masimo (NASDAQ:MASI) last announced its quarterly earnings results on Tuesday, August 6th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.77 by $0.09. Masimo had a net margin of 3.94% and a return on equity of 14.07%. The company had revenue of $496.30 million for the quarter, compared to the consensus estimate of $493.92 million. During the same period in the previous year, the firm posted $0.62 EPS. Masimo’s revenue for the quarter was up 9.0% compared to the same quarter last year. On average, equities analysts predict that Masimo will post 3.87 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on MASI shares. Piper Sandler increased their price target on Masimo from $160.00 to $165.00 and gave the company an overweight rating in a research note on Wednesday, August 7th. Needham & Company LLC reaffirmed a hold rating on shares of Masimo in a report on Friday, September 20th. Four research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of Moderate Buy and an average price target of $144.67.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.